November 18, 2016 - By Linda Rogers · 0 Comments
Oramed Pharmaceuticals Inc (NASDAQ:ORMP) institutional sentiment decreased to 0.44 in Q2 2016. Its down -0.42, from 0.86 in 2016Q1. The ratio has dropped, as 6 institutional investors increased or opened new positions, while 7 sold and reduced their stakes in Oramed Pharmaceuticals Inc. The institutional investors in our partner’s database reported: 195,487 shares, up from 177,240 shares in 2016Q1. Also, the number of institutional investors holding Oramed Pharmaceuticals Inc in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 2 Increased: 2 New Position: 4.
Oramed Pharmaceuticals Inc. is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. The company has a market cap of $84.14 million. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. It currently has negative earnings. The Firm is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
The stock decreased 0.15% or $0.01 on November 17, hitting $6.58. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) has declined 30.63% since April 18, 2016 and is downtrending. It has underperformed by 35.06% the S&P500.
Analysts await Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) to report earnings on November, 23. They expect $-0.21 earnings per share, down 10.53% or $0.02 from last year’s $-0.19 per share. After $-0.15 actual earnings per share reported by Oramed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 40.00% negative EPS growth.
According to Zacks Investment Research, “Oramed Pharmaceuticals, Inc. is a pharmaceutical company operating as a developer of oral drug delivery systems. The Company is developing orally ingestible insulin capsules for the treatment of diabetes as well as delivery solutions for other drugs and vaccines. Oramed Pharmaceuticals, Inc. is headquartered in Jerusalem, Israel.”
Financial Architects Inc holds 0.01% of its portfolio in Oramed Pharmaceuticals, Inc. for 3,450 shares. Tocqueville Asset Management L.P. owns 70,000 shares or 0.01% of their US portfolio. Moreover, Advisory Services Network Llc has 0% invested in the company for 1,086 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Bank Of Montreal Can, a Ontario – Canada-based fund reported 1,580 shares.#img1#
Ratings analysis reveals 100% of Oramed Pharmaceuticals’s analysts are positive. Out of 3 Wall Street analysts rating Oramed Pharmaceuticals, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $15 while the high is $25. The stock’s average target of $21.33 is 224.16% above today’s ($6.58) share price. ORMP was included in 5 notes of analysts from August 14, 2015. FBR Capital initiated the stock with “Outperform” rating in Thursday, November 19 report. The stock has “Sell” rating given by Zacks on Friday, August 14. The stock of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) earned “Buy” rating by Rodman & Renshaw on Friday, October 2. H.C. Wainwright maintained Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) rating on Tuesday, December 1. H.C. Wainwright has “Buy” rating and $25 price target. H.C. Wainwright initiated the shares of ORMP in a report on Thursday, October 1 with “Buy” rating.
Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a clinical-stage pharmaceutical company. The Firm is engaged in the field of oral delivery solutions for drugs delivered through injection. The Firm is also engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides.
More notable recent Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 21, 2011, also Quotes.Wsj.com with their article: “News Oramed Pharmaceuticals Inc.ORMP” published on February 11, 2013, Seekingalpha.com published: “Oramed Pharmaceuticals’ (ORMP) CEO Nadav Kidron Hosts Phase IIb Clinical …” on July 29, 2016. More interesting news about Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) were released by: Schaeffersresearch.com and their article: “Oramed Pharmaceuticals, Inc. (ORMP) Option Buyers, Analysts Anxious for Data” published on May 16, 2016 as well as Seekingalpha.com‘s news article titled: “Oramed: The Atypical Biotechnology Company With Great Upside Potential” with publication date: July 01, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers